Last reviewed · How we verify
Extended Release Subcutaneous Buprenorphine
At a glance
| Generic name | Extended Release Subcutaneous Buprenorphine |
|---|---|
| Also known as | Sublocade |
| Sponsor | Royal Victoria Hospital, Canada |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- INDV-6001 Multiple-Dose Pharmacokinetic Study (PHASE2)
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users (PHASE4)
- Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic (PHASE4)
- Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail (PHASE2, PHASE3)
- EXHIT ENTRE Comparative Effectiveness Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |